The latest price of a box of Pralsetinib, a targeted drug, and its influencing factors

In mainland China, the original drug Pralsetinib (Pralsetinib) is already on the market, but it is not yet included in the national medical insurance system, and patients need to pay for it in full at their own expense. Common packaging specifications are 100 mg×60 capsules and 100 There are two types of mg×120 tablets. Among them, the price of 60 tablets is usually around more than 20,000 yuan, while the price of 120 tablets is even higher, and can even reach 60,000 yuan per box in some areas. Due to different channels, taxes and logistics costs in different regions, there are certain differences in market prices. The high drug prices have brought huge economic pressure to patients who have been taking drugs for a long time.

In overseas markets, the price of Platinib’s original drug is generally higher. The price of a box of 60 capsules fluctuates between RMB 40,000 and more than 100,000 yuan. This is mainly affected by local pricing policies, exchange rate fluctuations and sales channels. In contrast, generic drugs of Platinib have appeared overseas, and their ingredients are basically the same as the original drug. Taking the generic version produced in Laos as an example, the price of 120 capsules is about more than 3,000 yuan, which has obvious cost advantages and is a relatively feasible alternative for patients with greater financial pressure.

The reasons for the high price of platinib mainly include research and development costs, clinical trial investment and marketing expenses. In addition, not being covered by medical insurance means that patients have to pay out of pocket, which directly drives up the burden of medication. In the international market, due to differences in drug patent protection policies, import tariffs, and profits in the circulation process in various countries, there is an obvious price gap. Although generic drugs can effectively lower prices, they are limited by production capacity, registration approval and sales channels, and it is difficult to completely replace the market share of original drugs in the short term.

In the future, the domestic price of platinib is expected to decrease through localized production and medical insurance negotiations. Once it enters the medical insurance directory, the patient's out-of-pocket payment ratio will be significantly reduced and drug accessibility will be greatly improved. At the same time, the further popularity of generic drugs and intensified market competition may also put continued downward pressure on the prices of original drugs. Taken together, policy support, localization process and international competition will become important factors affecting the price of platinib, which is of positive significance for improving the affordability of the drug for patients.

Reference materials:https://www.drugs.com/